Sepsis

Global Continuous Renal Replacement Therapy Market Analysis and Forecast Report 2024-2033 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024

The "Global Continuous Renal Replacement Therapy Market: Focus on Modality, Product, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Continuous Renal Replacement Therapy Market: Focus on Modality, Product, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
  • Key Questions Answered in this Report:
    What are the focus segments of the global continuous renal replacement therapy market in the upcoming years?
  • What are the major opportunities for existing market players and new entrants in the global continuous renal replacement therapy market?
  • What are the major opportunities for existing market players and new entrants in the global continuous renal replacement therapy market?

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Immunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID®

Retrieved on: 
Thursday, January 4, 2024

SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug Administration (FDA) for use with SeptiCyte RAPID®. The updated SeptiCyte® RAPID cartridges add undiluted EDTA blood as a validated sample type within the U.S. healthcare market and have been available on the European market since August 2022.

Key Points: 
  • SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug Administration (FDA) for use with SeptiCyte RAPID®.
  • The updated SeptiCyte® RAPID cartridges add undiluted EDTA blood as a validated sample type within the U.S. healthcare market and have been available on the European market since August 2022.
  • Their implementation allows for the use of standard EDTA blood collection tubes in place of proprietary PAXgene® blood RNA tubes.
  • BARDA awarded this grant to Immunexpress in 2020 as part of the DRIVe Solving Sepsis program.

Sigyn Therapeutics Releases Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024

SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce.

Key Points: 
  • SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce.
  • The goal of this letter is to help you better understand our opportunities, our challenges, and decision-making processes.
  • In that submission, our endeavors were solely predicated on the development and clinical advancement of Sigyn TherapyTM.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties.

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Erelzi, etanercept, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised